Protective antibodies against diphtheria, tetanus, and pertussis following revaccination in children and young adults having undergone haematopoietic stem cell transplantation.

IF 1.7 Q2 MULTIDISCIPLINARY SCIENCES

BMC Research Notes Pub Date : 2025-07-01 DOI:10.1186/s13104-025-07332-x

Ravipreeya Sukswadi Na Ayudhya, Chanya Pongpatipat, Usanarat Anurathapan, Samart Pakakasama, Suradej Hongeng, Chompunuch Klinmalai, Nopporn Apiwattanakul

{"title":"Protective antibodies against diphtheria, tetanus, and pertussis following revaccination in children and young adults having undergone haematopoietic stem cell transplantation.","authors":"Ravipreeya Sukswadi Na Ayudhya, Chanya Pongpatipat, Usanarat Anurathapan, Samart Pakakasama, Suradej Hongeng, Chompunuch Klinmalai, Nopporn Apiwattanakul","doi":"10.1186/s13104-025-07332-x","DOIUrl":null,"url":null,"abstract":"Objective: Haematopoietic stem cell transplantation (HSCT) eliminates pre-existing immunity, necessitating revaccination. This study aimed to assess the prevalence of protective antibody titres against diphtheria, pertussis, and tetanus in pediatric and young adult HSCT recipients at least four years post-revaccination.Results: A cross-sectional study was conducted in 94 post-HSCT patients (aged 5-25 years) who completed a three-dose DTP series at least four years prior. Protective anti-tetanus and anti-diphtheria antibody titres were detected in 93.6% and 81.9% of participants, respectively, at least four years post-revaccination. However, only 9.4% had protective anti-pertussis titres, which remained low within five years of revaccination. Factors associated with protective anti-tetanus included higher absolute lymphocyte counts (ALC) 1-year post-revaccination, while corticosteroid use during revaccination was negatively associated. ALC at the 3rd dose of vaccination was associated with a protective anti-diphtheria titre. A booster dose of Tdap resulted in seroconversion in 80.0% for diphtheria, 47.4% for pertussis, and 100% for tetanus. These findings support an earlier booster dose of DTP vaccination in post-HSCT patients.","PeriodicalId":9234,"journal":{"name":"BMC Research Notes","volume":"18 1","pages":"251"},"PeriodicalIF":1.7000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12210706/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMC Research Notes","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s13104-025-07332-x","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MULTIDISCIPLINARY SCIENCES","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: Haematopoietic stem cell transplantation (HSCT) eliminates pre-existing immunity, necessitating revaccination. This study aimed to assess the prevalence of protective antibody titres against diphtheria, pertussis, and tetanus in pediatric and young adult HSCT recipients at least four years post-revaccination.

Results: A cross-sectional study was conducted in 94 post-HSCT patients (aged 5-25 years) who completed a three-dose DTP series at least four years prior. Protective anti-tetanus and anti-diphtheria antibody titres were detected in 93.6% and 81.9% of participants, respectively, at least four years post-revaccination. However, only 9.4% had protective anti-pertussis titres, which remained low within five years of revaccination. Factors associated with protective anti-tetanus included higher absolute lymphocyte counts (ALC) 1-year post-revaccination, while corticosteroid use during revaccination was negatively associated. ALC at the 3rd dose of vaccination was associated with a protective anti-diphtheria titre. A booster dose of Tdap resulted in seroconversion in 80.0% for diphtheria, 47.4% for pertussis, and 100% for tetanus. These findings support an earlier booster dose of DTP vaccination in post-HSCT patients.

查看原文本刊更多论文

在接受造血干细胞移植的儿童和年轻人中，再次接种疫苗后可产生白喉、破伤风和百日咳的保护性抗体。

目的：造血干细胞移植（HSCT）消除了预先存在的免疫，需要重新接种疫苗。本研究旨在评估再次接种疫苗至少四年后，儿童和年轻成人HSCT受者中针对白喉、百日咳和破伤风的保护性抗体滴度的流行情况。结果：一项横断面研究对94例hsct后患者（5-25岁）进行了研究，这些患者至少在4年前完成了三剂DTP系列治疗。在再次接种疫苗至少四年后，分别有93.6%和81.9%的参与者检测到抗破伤风和抗白喉抗体滴度。然而，只有9.4%的人具有抗百日咳的保护性滴度，这在重新接种疫苗的五年内仍然很低。与保护性抗破伤风相关的因素包括再次接种疫苗1年后较高的绝对淋巴细胞计数（ALC），而在再次接种疫苗期间使用皮质类固醇呈负相关。第三次接种时的ALC与保护性抗白喉滴度有关。白喉加强剂的血清转化率为80.0%，百日咳为47.4%，破伤风为100%。这些发现支持在hsct后患者早期加强接种百白破疫苗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

BMC Research Notes Biochemistry, Genetics and Molecular Biology-Biochemistry, Genetics and Molecular Biology (all)

CiteScore

3.60

自引率

0.00%

发文量

363

审稿时长

15 weeks

期刊介绍： BMC Research Notes publishes scientifically valid research outputs that cannot be considered as full research or methodology articles. We support the research community across all scientific and clinical disciplines by providing an open access forum for sharing data and useful information; this includes, but is not limited to, updates to previous work, additions to established methods, short publications, null results, research proposals and data management plans.